- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05999513
A Relative Bioavailability Study and Food Effect Study of AB521 in Healthy Adult Volunteers (ARC-28)
A Phase 1, Open-Label, Randomized, Single-Dose, 3-Treatment, 3-Way Crossover, Pharmacokinetic Study to Evaluate the Relative Bioavailability of AB521 Tablet and Capsule Formulations and the Effect of Food on the Pharmacokinetics of the Tablet Formulation in Healthy Adult Volunteers
Study Overview
Study Type
Enrollment (Actual)
Phase
- Phase 1
Contacts and Locations
Study Locations
-
-
Nebraska
-
Lincoln, Nebraska, United States, 68502
- Celerion, Inc.
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Key Inclusion Criteria:
- Continuous non-smoker who has not used nicotine- and tobacco-containing products for at least 3 months prior to the first dosing based on volunteer self-reporting
- Body mass index (BMI) ≥ 18.0 and ≤ 32.0 kilogram (kg)/square meter (m^2) at the screening visit, with body weight ≥ 45 kg
- Medically healthy with no clinically significant medical history, physical examination, laboratory profiles, vital signs, and ECGs, as deemed by the study physician
- Able to swallow multiple capsules and tablets
- Has adequate peripheral venous access
Key Exclusion Criteria:
- Has active neoplastic disease or history of neoplastic disease within 5 years of the screening visit (except for basal or squamous cell carcinoma of the skin or carcinoma in situ that has been definitively treated with standard of care)
- Has abnormal liver enzyme test results or hematology values at the time of enrollment
- Has a history of additional risk factors for Torsades de pointes (example: heart failure, hypokalemia, family history of Long QT Syndrome)
- Malabsorption condition that would alter the absorption of orally administered medications at the discretion of the study physician
- Participation in another clinical study within 90 days or within 5 half-lives (if known), prior to the first dosing, whichever is longer. The 90-day window will be derived from the date of the last blood collection or dosing, whichever is later, in the previous study to Day 1 of the current study
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: AB521 - Sequence ABC
Participants will sequentially receive AB521 capsules fasted (Treatment A), followed by AB521 tablets fasted (Treatment B), followed by AB521 tablets fed (Treatment C)
|
Administered as specified in the treatment arm
|
Experimental: AB521 - Sequence BCA
Participants will sequentially receive Treatment B, followed by Treatment C, then Treatment A
|
Administered as specified in the treatment arm
|
Experimental: AB521 - Sequence CAB
Participants will sequentially receive Treatment C, followed by Treatment A, then Treatment B
|
Administered as specified in the treatment arm
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Area Under the Plasma Drug Concentration-Time Curve (AUC)
Time Frame: Predose, Up to 168 hours postdose
|
Predose, Up to 168 hours postdose
|
Maximum Concentration (Cmax)
Time Frame: Predose, Up to 168 hours postdose
|
Predose, Up to 168 hours postdose
|
Time to Maximum Concentration (Tmax)
Time Frame: Predose, Up to 168 hours postdose
|
Predose, Up to 168 hours postdose
|
Terminal Half-Life Time (t1/2)
Time Frame: Predose, Up to 168 hours postdose
|
Predose, Up to 168 hours postdose
|
Apparent Total Plasma Clearance (CL/F)
Time Frame: Predose, Up to 168 hours postdose
|
Predose, Up to 168 hours postdose
|
Apparent Volume of Distribution During the Terminal Elimination Phase (Vz/F)
Time Frame: Predose, Up to 168 hours postdose
|
Predose, Up to 168 hours postdose
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Number of Participants With Adverse Events
Time Frame: Up to 10 weeks
|
Up to 10 weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Director: Medical Director, Arcus Biosciences
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Other Study ID Numbers
- ARC-28
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Arcus will provide access to individual de-identified participant data and related study documents (e.g., protocol, Statistical Analysis Plan [SAP], Clinical Study Report [CSR]) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions.
For more information, please visit our website.
IPD Sharing Supporting Information Type
- STUDY_PROTOCOL
- SAP
- CSR
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Healthy Participants
-
PfizerRecruitingHealthy Subjects | Healthy ParticipantsUnited States
-
PfizerNot yet recruiting
-
PfizerNot yet recruiting
-
Insmed IncorporatedRecruitingHealthy ParticipantsUnited States
-
Aeovian Pharmaceuticals, Inc.RecruitingHealthy ParticipantsAustralia
-
Suzhou Zelgen Biopharmaceuticals Co.,LtdRecruitingHealthy ParticipantsChina
-
CelgeneRecruitingHealthy ParticipantsUnited States
-
Bristol-Myers SquibbRecruiting
-
AstraZenecaParexelRecruiting
-
ProMis Neurosciences, IncRecruiting
Clinical Trials on AB521
-
Arcus Biosciences, Inc.RecruitingClear Cell Renal Cell Carcinoma | Solid TumorsKorea, Republic of, United States
-
ExelixisArcus Biosciences, Inc.RecruitingAdvanced Clear Cell Renal Cell Carcinoma or Other Advanced Solid TumorsUnited States
-
Arcus Biosciences, Inc.CompletedHealthy ParticipantsNetherlands